Navigation Links
Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Date:11/7/2011

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a planned interim analysis of a Phase 2b study, SOUND-C2, that showed the combination of two oral direct acting hepatitis C virus (HCV) compounds – the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127 with ribavirin (RBV) – was successful in reducing viral load below the lower limit of quantifiable levels at week 12 (viral response) in the majority of treatment-naive patients infected with chronic genotype-1 (GT1) HCV. None of the five study arms included treatment with interferon. These data were presented as a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, CA.

"Results from the planned interim analysis of SOUND-C2 are encouraging," said Stefan Zeuzem, M.D., Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany and lead investigator of the study. "They show that BI 201335 plus BI 207127 with ribavirin suppressed the hepatitis C virus to undetectable levels in the majority of patients in this study. We must now complete the study to confirm if this interferon-free regimen leads to a sustained viral response."

"BI is developing our dual oral direct acting antiviral treatment regimen with the goal of eliminating interferon from HCV treatment. We are excited by these interim results and look forward to final study outcomes," said Peter Piliero, M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We also are pleased to present other data from our hepatitis C virus portfolio that underscores our ongoing focus on real-world challenges faced by HCV patients, including traditionally difficult-to-treat populations."

The interferon-free oral combination therapy arms with B
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
2. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
3. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
5. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
6. Hepatitis C Phase 2A Trial Positive Results
7. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
9. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
10. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... NEW YORK , May 27, 2015 ... Summary Sepsis patients suffer from a series ... and/or their toxins in the blood or tissues, which ... cellular dysfunction leading to mortality rates near 50% depending ... on the national healthcare systems of the global marketplace, ...
(Date:5/27/2015)... May 27, 2015 The prevalence of cardiovascular ... accelerated aging of population and changes in consumption concept, ... been growing year after year, thereby promoting the development ... in China totaled 454,505 in ... interventional cardiovascular device industry there was worth RMB20.12 billion. ...
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/f6rkcf/north_america ) ... Portable X Ray Devices Market - Growth, Trends ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... for Portable X-Ray Devices is expected to grow ... X-Ray is a form of electromagnetic ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2
... Center is,seeking local residents with type 2 diabetes ... study evaluating an investigational,device, the TANTALUS System. Diabetes ... TANTALUS System is an implantable device that delivers ... The primary objective of the,randomized, double-blind controlled study ...
... successfully targets human leukemic stem cells, ATLANTA, ... has today presented data at the American Society,of ... promising,pre-clinical activity of a novel monoclonal antibody, in ... AML is an aggressive cancer of white blood ...
Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3
(Date:5/27/2015)... In support of a new study ... Journal of American Geriatrics Society about the link between ... Commons OB-GYN P.A . is reiterating the nutritional value ... , To examine the relationship between diet soda intake ... Study of Aging (SALSA) tracked the soda consumption of ...
(Date:5/27/2015)... 2015 The Case Management Society ... to provide CMSA's Career and Knowledge Pathways educational ... to strengthen the case/care management workforce by offering ... The mutually beneficial agreement provides Medix, a workforce ... talent in the healthcare, scientific and IT industries, ...
(Date:5/27/2015)... 2015 SAN DIEGO, May 27, ... is the first healthcare provider along the Gulf ... care management (CCM). In partnership with MD Revolution, ... RevUp, a new program that enables healthcare providers ... monthly reimbursements. This new, user-friendly program is designed ...
(Date:5/27/2015)... HOUSTON, Tx (PRWEB) May 27, 2015 ... combined germline pharmacogenomic and somatic genomic analysis in personalized ... was published by the American Society of Clinical Oncology ... – June 2 in Chicago. , The molecular and ... The Cancer Genome Atlas (TCGA) database. The study reports ...
(Date:5/27/2015)... On June 5, Plan B [the agency alternative], ... to host Donate Your Break, a public blood drive. ... donor coach outside of 116 W. Illinois (at LaSalle) ... whole blood units is highest for LifeSource, the largest ... requires approximately 1,000 donations per day to maintain an ...
Breaking Medicine News(10 mins):Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2
... NY, July 1, 2010 The Damon Runyon ... Clinical Investigators at its April 2010 Clinical Investigator ... prestigious three-year award are outstanding early career physician-scientists ... under the mentorship of the nation,s leading scientists ...
... meet a multitude of people on a daily basis: the ... bus driver or the colleagues at the office. Without the ... be able to distinguish between people. Monkeys also possess the ... extract the relevant information about the individual directly from the ...
... ... it has expanded the implementation of its state-of-the-art Electronic Medical Records (EMR) system to 21 ... Putnam and Orange Counties and northern New Jersey. All of our Westchester, Putnam, Orange County ... ...
... The ... ... global on-demand web-application company, today announced the launch of WorldAPP Community, an online forum where ... data collection process. , , , , , The WorldAPP Community consists of three ...
... study adds to the mounting evidence that older adults commonly ... may be a risk factor for the metabolic syndrome, a ... presented at The Endocrine Society,s 92nd Annual Meeting in San ... diabetes and cardiovascular disease, an adequate vitamin D level in ...
... human protein significantly decreases disease signs of asthma in ... for patients who do not respond to current steroid ... were presented at The Endocrine Society,s 92nd Annual Meeting ... binding protein-3 (IGFBP-3), uniquely inhibits specific physiological consequences of ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 3Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 4Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 5Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 6Health News:Recognition at first glance 2Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 2Health News:ENT and Allergy Associates, LLP Expands its New Electronic Practice Management System (EMR) 3Health News:WorldAPP Launches User Community 2Health News:WorldAPP Launches User Community 3Health News:Low vitamin D linked to the metabolic syndrome in elderly people 2Health News:Experimental nonsteroidal treatment of asthma shows promise 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: